1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsVITAL: Proof-of-Concept Funding is sponsored by BARDA. Provides funding for 6-month, milestone-based projects that support the development, evaluation, and validation of therapeutic multi-use/platform solutions aligned with BARDA's mission.
Get alerted about grants like this
Save a search for “BARDA” or related topics and get emailed when new opportunities appear.
Search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Awards for Development, Evaluation, and Validation of Innovative Therapeutics Solutions Applications for 2025 are now closed. Join our mailing list to be the first to know about upcoming opportunities. Non-Dilutive Funding to Advance Your Therapeutics Innovations Are you working on groundbreaking therapeutics solutions?
The VITAL Hub seeks proposals for the development of innovative therapeutics solutions in alignment with BARDA’s mission to promote health security. Multi-use/platform technologies are preferred for this solicitation. VITAL invites startups and university-backed projects to apply for non-dilutive funding from $50K to $200K.
We are seeking product development-focused solutions in the following topic areas: Targeting therapeutics to/within different types of cells and tissues for a faster, more effective, and more durable response Including, but not limited to, novel innovations to optimize route of administration, nanoparticles/conjugates for selective delivery, and strategies to recruit specific immune cell populations to enhance response Activating the innate immune system for faster, more effective, and more durable protection Including, but not limited to, therapeutics that act directly to stimulate the innate immune system as well as those that modify the activity of innate immune regulators to enhance response Promoting rapid recovery from radiological and nuclear threats such as acute radiation exposure and uncontrolled hemorrhage Including, but not limited to, cell and cell product-based therapeutics that promote hematopoiesis and tissue and organ regeneration, as well as next-generation blood products The review period for full applications for DEV Funding is currently paused.
VITAL expects to resume actively reviewing full applications in March 2025. Preliminary Applications may be submitted anytime and are assessed on an ongoing basis. If funding becomes available, organizations may be invited to submit a full proposal outside of the standard funding cycle.
Otherwise, VITAL will invite select organizations to submit full applications during the next cycle of review (expected January – March 2025). Click HERE to submit a Preliminary Application. If your organization does not wish to submit a Preliminary Application at this time but would like to be notified by email when VITAL resumes actively reviewing full applications, please click HERE and fill out this form.
Milestone-based Awards From $50K – $200K For 6-Month Long Projects Of Innovative Product Development-Focused Therapeutics Solutions Aligned with BARDA’s Mission* *For more information on BARDA areas of interest, visit https://drive. hhs. gov/partner.
html. BARDA also recently released TPPs relevant to some of its areas of interest: https://medicalcountermeasures. gov/barda/tpp.
Startups and projects will receive project management support and regular mentoring from subject matter experts over the award duration (6 months).
Funding Can Be Used To Demonstrate: Proof-of-concept for a BARDA-relevant use case for an existing platform technology Proof-of-concept for high-risk breakthrough technologies Advancement of technologies currently in development to the next value inflection points BARDA primarily develops medical countermeasures to counter acute threats and does not support research and development or acceleration in the areas of oncology or chronic disease.
However, BARDA does partner with innovators and companies developing platform and multi-use technologies. Applicants can include data from other use cases so long as BARDA funding will be used to support research and development of the BARDA-relevant use cases. Applications for DEV Funding Are Now Closed Pre-proposal applications are now closed.
Stay tuned for additional funding programs! Full Application Invitation Applicants advancing to the next stage will be notified by November 2025 to submit a full application (by invitation only). Winter 2025/2026 – Awardees will be selected and notified by early 2026.
Preliminary Applications may be submitted anytime and are assessed on an ongoing basis. If funding becomes available, organizations may be invited to submit a full proposal outside of the standard funding cycle. Otherwise, VITAL will invite select organizations to submit full applications during the next cycle of review (expected January – March 2025).
Click HERE to submit a Preliminary Application. If your organization does not wish to submit a Preliminary Application at this time but would like to be notified by email when VITAL resumes actively reviewing full applications, please click HERE and fill out this form. VITAL Insights On-Demand: Watch Our Webinar Info Session Join one of our live webinars by signing up to a session here .
If you or your organization would like to explore collaborations with other potential applicants, please visit our DEV Teaming Page .
Targeting therapeutics to/within different types of cells and tissues for a faster, more effective, and more durable response Including, but not limited to, novel innovations to optimize route of administration, nanoparticles/conjugates for selective delivery, and strategies to recruit specific immune cell populations to enhance response Activating the innate immune system for faster, more effective, and more durable protection Including, but not limited to, therapeutics that act directly to stimulate the innate immune system as well as those that modify the activity of innate immune regulators to enhance response Promoting rapid recovery from radiological and nuclear threats such as acute radiation exposure and uncontrolled hemorrhage Including, but not limited to, cell and cell product-based therapeutics that promote hematopoiesis and tissue and organ regeneration, as well as next-generation blood products For more information on BARDA areas of interest, visit https://www.
medicalcountermeasures. gov/barda/barda-baa . BARDA also recently released TPPs relevant to some of its areas of interest: https://medicalcountermeasures.
gov/barda/tpp . We are accepting applications from early-stage biotech companies as well as academic and other innovators globally. Eligibility To Apply For The Accelerator Program AND Non-Dilutive Funding Do I or my collaborators need to register with the System for Award Management (SAM)?
No. SAM. gov registration is not required.
Application & Program Timeline Application Deadline : September 26, 2025 Notification of Awards : Early 2026 Program Start : Mid-March 2026 Application Review Criteria Applications will be evaluated with a particular focus on 1) the ability of the proposed application of the technology to support BARDA’s mission, 2) the uniqueness of the innovation and its ability to address unmet needs, and 3) the capacity for the proposed use of funds to advance the technology to the next value inflection point.
Expected Funding Duration It is anticipated that project milestones will be completed in 6 months from the start of the project, and that the funding will be spent during this time period. Project management and mentor support will be provided during this 6-month period. VITAL and BARDA also understand that unforeseen and unpredicted events happen during development, evaluation and validation activities.
There will be reporting requirements on a quarterly basis, based on milestones achievement, and a final report. Allow expenses for the non-dilutive funds from VITAL include: direct costs for development, evaluation, or validation activities, and labor for personnel or CROs “doing the work”. Indirect costs are permitted but count toward the total cost limit, which is capped at $200K.
Access to BARDA Subject Matter Experts and Resources Companies and individuals that receive funding from VITAL will have access to BARDA subject matter experts and other related BARDA resources. Access to these BARDA resources will be managed and coordinated by the VITAL Lead Mentor. Is my technology most aligned to the VITAL Hub or another BARDA Accelerator Network Hub?
VITAL is one of 5 BARDA Accelerator Network hubs. The other 4 are I-CREATE (diagnostics and medical devices), PARATUS (digital health), BioTools Innovator VANGUARD (enabling technologies), and SPARK (innovations in pediatrics). Innovators developing models for vaccines/therapeutics discovery may want to look into opportunities with the PARATUS and VANGUARD hubs in addition to VITAL, depending on the underlying technology.
If your technology could significantly and specifically improve sampling, delivery, efficacy, durability, etc., of vaccines/therapeutics for pediatric populations, you may want to look into opportunities with the SPARK hub in additional to VITAL. VITAL will not fund technologies specific to antimicrobial resistance (AMR) under this solicitation, including diagnostics, vaccines, and therapeutics.
If you are developing AMR innovations, please visit the CARB-X program website to view current funding priorities: https://carb-x. org/apply/funding-themes/ Gain of Function Research This funding opportunity does not support gain of function research or research that involves the manipulation of pathogens resulting in potential gain of function. Proposals will be evaluated for the appropriate use of strain(s) in proposed studies.
BARDA DRIVe: https://drive. hhs. gov/partner.
html BARDA BAA funding: https://medicalcountermeasures. gov/barda/barda-baa/ BARDA’s main page: www. medicalcountermeasures.
gov Does your technology not fit under one of the current focus areas, but aligns with BARDA’s mission? VITAL reviews applications on a rolling basis, and applicants are invited to submit a full proposal based on BARDA priorities and availability of funds.
Based on current listing details, eligibility includes: Nonprofits, Universities, State/local governments, Private sector companies. Applicants should confirm final requirements in the official notice before submission.
Current published award information indicates $50,000 - $200,000 Always verify allowable costs, matching requirements, and funding caps directly in the sponsor documentation.
The current target date is rolling deadlines or periodic funding windows. Build your timeline backwards from this date to cover registrations, approvals, attachments, and final submission checks.
Federal grant success rates typically range from 10-30%, varying by agency and program. Build a strong proposal with clear objectives, measurable outcomes, and a well-justified budget to improve your chances.
Requirements vary by sponsor, but typically include a project narrative, budget justification, organizational capability statement, and key personnel CVs. Check the official notice for the complete list of required attachments.
Yes — AI tools like Granted can help research funders, draft proposal sections, and check compliance. However, always review and customize AI-generated content to reflect your organization's unique strengths and the specific requirements of the solicitation.
Review timelines vary by funder. Federal agencies typically take 3-6 months from submission to award notification. Foundation grants may be faster, often 1-3 months. Check the program's timeline in the official solicitation for specific dates.
Many federal programs offer multi-year funding or allow competitive renewals. Check the official solicitation for continuation and renewal policies. Non-competing continuation applications are common for multi-year awards.